355
Participants
Start Date
October 31, 2012
Primary Completion Date
April 30, 2014
Study Completion Date
May 31, 2014
Alirocumab
Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Atorvastatin
Atorvastatin over-encapsulated tablets orally.
Ezetimibe
Ezetimibe over-encapsulated tablet orally.
Rosuvastatin
Rosuvastatin over-encapsulated tablets orally.
Placebo
Placebo for alirocumab and ezetimibe.
Mobile
Chandler
Tucson
Anaheim
Beverly Hills
Lakeland Village
Newport Beach
Northridge
Sacramento
Walnut Creek
Milford
Atlantis
Boca Raton
Clearwater
Jacksonville
Miami (2 Locations)
Oviedo
Pinellas Park
Port Orange
Sarasota
Tampa
West Palm Beach
Boise
Meridian
Chicago
Morton
Indianapolis
Newton
Overland Park
Wichita
Lexington
Louisville
Auburn
Bethesda
Edina
Rochester
Olive Branch
Port Gibson
St Louis
Butte
Las Vegas
Williamsville
Winston-Salem
Cleveland
Oklahoma City
Warwick
Greer
Summerville
Kingsport
Dallas (2 Locations)
Fort Worth
Houston
Bountiful
Marion
Salt Lake City
Renton
Herston QLD
New Lambton Heights
Perth
Sherwood
Woolloongabba
Brampton
Etobicoke
London
Newmarke
Thornhill
Toronto
Chicoutimi
Dijon
Lille
Vénissieux
Bad Oeynhausen
Berlin
Cologne
Munich
Regensburg
Ulm
Chiete
Genova
Napoli
Palermo
Roma (2 Locations)
Distrito Federal
Guadalajara
Guadalajara, Jalisco
Monterrey Nuevo Leon
Tijuana Baja California
Zapopan Jalisco
Barcelona (3 Locations)
Madrid
Sant Joan Despí
Carmarthen
Chester
Peterborough
Salford
Stevenage
West Bromwich, West Midlands
Collaborators (1)
Sanofi
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY